{"id":"W2128030263","doi":"10.1016/s0140-6736(12)60771-5","title":"Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"PCSK9; Ezetimibe; Medicine; Evolocumab; Alirocumab; Placebo; Internal medicine; Statin; Gastroenterology; Population; Familial hypercholesterolemia; Tolerability; Clinical endpoint; Cholesterol; Apolipoprotein B; Endocrinology; Lipoprotein; Randomized controlled trial; Adverse effect; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001271117,0.002399438,0.003826745,0.0004408899,0.0003900982,0.00115426,0.0008773144,0.00214877,0.005904648],"category_scores_gemma":[0.00134433,0.000841699,0.00255069,0.0003805181,0.001191256,0.001039715,0.0004101782,0.003025458,0.001243459],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008002121,"about_ca_system_score_gemma":0.0006512161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001665762,"about_ca_topic_score_gemma":0.003083793,"domain_scores_codex":[0.9995523,0.0001770565,0.00003889983,0.0001076648,0.00003806077,0.00008612045],"domain_scores_gemma":[0.9995705,0.0001145491,0.0000883731,0.0000402975,0.00003300782,0.0001531682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.985711,0.001681556,0.0004684513,0.0005655081,0.001767936,0.0000470985,0.00003102807,0.000163797,0.001911828,0.00005699103,0.0004878094,0.007106855],"study_design_scores_gemma":[0.9744459,0.02200784,0.001631049,0.00002520658,0.001093101,0.00002785156,0.00001956235,0.0001767902,0.000193144,0.00008121326,0.0002858641,0.00001254276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857438,0.007179858,0.0005562755,0.001174413,0.001055061,0.001260523,0.0008995401,0.0001628138,0.001967655],"genre_scores_gemma":[0.9887628,0.003396557,0.0008111267,0.001348123,0.0005941986,0.001084235,0.00096019,0.0000242218,0.003018518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005904648,"threshold_uncertainty_score":0.01975298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01989425375777931,"score_gpt":0.3207090111616874,"score_spread":0.3008147574039081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}